SCHEMBL3106941

SCHEMBL3106941

O=C(c1ccc2c(c1)-c1ccccc1C2)N1[C@@H]2CC[C@@H]1CC(O)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.47
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
DRD2 P14416 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
HTR2B P41595 1/20 0.41
ELOVL6 Q9H5J4 1/20 0.40
VNN1 O95497 1/20 0.39
KDM4E B2RXH2 3/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13431290 1.00 SRD5A2 (0.47) SRD5A2PRMT5WDR77DRD2ADRA1D
SCHEMBL3225516 1.00 SRD5A2 (0.47) SRD5A2PRMT5WDR77DRD2ADRA1D
SCHEMBL21162194 0.76 ELOVL6 (0.53) ELOVL6VNN1KDM4EALDH1A1HPGD
SCHEMBL24311418 0.73 SRD5A2 (0.62) SRD5A2DRD2ADRA1DHTR2AHTR2C
SCHEMBL3116608 0.71 TTR (0.43) PRMT5WDR77HTR2BELOVL6VNN1
SCHEMBL3104475 0.71 KDM4E (0.45) VNN1KDM4EALDH1A1HPGDMAPT
SCHEMBL31069845 0.71 SRD5A2 (0.86) SRD5A2DRD2ADRA1DHTR2AHTR2C
SCHEMBL29709873 0.71 SRD5A2 (0.86) SRD5A2DRD2ADRA1DHTR2AHTR2C
SCHEMBL3105349 0.71 SRD5A2 (0.86) SRD5A2DRD2ADRA1DHTR2AHTR2C
SCHEMBL2019989 0.70 KDM4E (0.56) KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056600-A1 11BETA-HSD1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC 2010-03-04 US claimed
EP-2141990-A1 11BETA-HSD1 ACTIVE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2010-01-13 EP claimed
WO-2008119017-A1 11BETA-HSD1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-10-02 WO claimed
US-20100056600-A1 11BETA-HSD1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC 2010-03-04 US disclosed
EP-2141990-A1 11BETA-HSD1 ACTIVE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2010-01-13 EP disclosed
WO-2008119017-A1 11BETA-HSD1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056600-A1 11BETA-HSD1 ACTIVE COMPOUNDS HSD11B1, HSD3B1, HSD11B2 SRD5A2 25/4885PRMT5 2753/4885WDR77 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.